Neuland Laboratories Limited (NEULANDLAB.NS)
INR 10962.35
(-4.17%)
INR 10962.35
(-4.17%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 449.2 Million INR | -42.48% |
| 2022 | 780.93 Million INR | -29.76% |
| 2021 | 1.11 Billion INR | 13.78% |
| 2020 | 977.18 Million INR | 22.22% |
| 2019 | 799.5 Million INR | 31.68% |
| 2018 | 607.15 Million INR | -41.33% |
| 2017 | 1.03 Billion INR | 146.78% |
| 2016 | 419.35 Million INR | -7.63% |
| 2015 | 454 Million INR | 36.66% |
| 2014 | 332.21 Million INR | -1.91% |
| 2013 | 338.7 Million INR | -33.73% |
| 2012 | 511.1 Million INR | -8.57% |
| 2011 | 559 Million INR | -76.08% |
| 2010 | 2.33 Billion INR | 0.24% |
| 2009 | 2.33 Billion INR | 16.41% |
| 2008 | 2 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 610.4 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 449.2 Million INR | -42.48% |
| 2023 Q4 | 449.2 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 780.93 Million INR | 0.0% |
| 2022 FY | 780.93 Million INR | -29.76% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 959.37 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 1.11 Billion INR | 13.78% |
| 2021 Q4 | 1.11 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 1.11 Billion INR | 0.0% |
| 2020 Q2 | 958.65 Million INR | 0.0% |
| 2020 Q4 | 977.18 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 977.18 Million INR | 22.22% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 799.5 Million INR | 31.68% |
| 2019 Q2 | 539.71 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 799.5 Million INR | 0.0% |
| 2018 Q4 | 607.15 Million INR | 0.0% |
| 2018 FY | 607.15 Million INR | -41.33% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 1.03 Billion INR | 146.78% |
| 2016 FY | 419.35 Million INR | -7.63% |
| 2016 Q3 | 419.35 Million INR | -12.07% |
| 2016 Q2 | 476.94 Million INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2016 Q4 | 298.07 Million INR | -28.92% |
| 2015 FY | 454 Million INR | 36.66% |
| 2014 FY | 332.21 Million INR | -1.91% |
| 2013 FY | 338.7 Million INR | -33.73% |
| 2012 FY | 511.1 Million INR | -8.57% |
| 2011 FY | 559 Million INR | -76.08% |
| 2010 FY | 2.33 Billion INR | 0.24% |
| 2009 FY | 2.33 Billion INR | 16.41% |
| 2008 FY | 2 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 28.561% |
| Bafna Pharmaceuticals Limited | 107.53 Million INR | -317.742% |
| FDC Limited | 2.46 Million INR | -18115.977% |
| Gufic Biosciences Limited | 1.53 Billion INR | 70.824% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 98.582% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 67.984% |
| Orchid Pharma Limited | 1.2 Billion INR | 62.7% |
| Alkem Laboratories Limited | 400 Million INR | -12.302% |
| Bajaj HealthCare Limited | 650.34 Million INR | 30.928% |
| Brooks Laboratories Limited | 3.56 Million INR | -12500.449% |
| Eris Lifesciences Limited | 6.54 Billion INR | 93.137% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -204.319% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | 61.75% |
| Innova Captab Limited | 2.1 Billion INR | 78.662% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -494.424% |
| Wanbury Limited | 820 Million INR | 45.219% |
| Lupin Limited | 1.55 Billion INR | 71.071% |
| Aarti Drugs Limited | 2.75 Billion INR | 83.685% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -112201.5% |
| Albert David Limited | 6.01 Million INR | -7366.855% |
| Alembic Limited | 73.9 Million INR | -507.857% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Hester Biosciences Limited | 1.81 Billion INR | 75.288% |
| Hikal Limited | 4.22 Billion INR | 89.377% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -302.421% |
| Ind-Swift Limited | 10.09 Billion INR | 95.55% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -236.381% |
| Medico Remedies Limited | 8.67 Million INR | -5079.958% |
| Morepen Laboratories Limited | 33.64 Million INR | -1235.333% |
| Procter & Gamble Health Limited | 68.8 Million INR | -552.916% |
| RPG Life Sciences Limited | -30.3 Million INR | 1582.528% |
| Sigachi Industries Limited | 265.79 Million INR | -69.003% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -3277.489% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -111.534% |
| Themis Medicare Limited | 267.74 Million INR | -67.777% |
| Unichem Laboratories Limited | 382.22 Million INR | -17.525% |
| Vaishali Pharma Limited | 35.98 Million INR | -1148.384% |
| Venus Remedies Limited | 386.8 Million INR | -16.134% |
| Windlas Biotech Limited | 20.18 Million INR | -2125.996% |
| ZIM Laboratories Limited | 356 Million INR | -26.179% |
| Sakar Healthcare Limited | 549.55 Million INR | 18.259% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 97.896% |
| Divi's Laboratories Limited | 20 Million INR | -2146.03% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -1513.759% |
| Mankind Pharma Limited | 325.81 Million INR | -37.871% |
| Sequent Scientific Limited | 1.42 Billion INR | 68.525% |
| Laurus Labs Limited | 7.98 Billion INR | 94.372% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -90.019% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 70.387% |
| Zydus Lifesciences Limited | 251 Million INR | -78.967% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -3115.965% |
| Wockhardt Limited | 8.91 Billion INR | 94.958% |
| Bal Pharma Limited | 363.82 Million INR | -23.468% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 92.501% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -26.209% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -4782.674% |
| Shilpa Medicare Limited | 5.6 Billion INR | 91.981% |
| Valiant Laboratories Limited | 750.89 Million INR | 40.178% |
| Ajanta Pharma Limited | 235.2 Million INR | -90.989% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -1293.156% |
| Granules India Limited | 689.71 Million INR | 34.87% |
| Medicamen Biotech Limited | 12.55 Million INR | -3477.905% |
| Ipca Laboratories Limited | 5.8 Billion INR | 92.261% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 36950.369% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.916% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 97.199% |
| NATCO Pharma Limited | 53 Million INR | -747.558% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 75.52% |
| Strides Pharma Science Limited | 6.71 Billion INR | 93.31% |
| Indoco Remedies Limited | 3.51 Billion INR | 87.229% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -321.394% |